Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7CNS 1

Conditions

Brain Neoplasms 1699Glioblastoma 1307Glioma 992Neuroblastoma 408Central Nervous System Neoplasms 384Astrocytoma 383Gliosarcoma 286Oligodendroglioma 237Neoplasms 226Breast Neoplasms 216Meningioma 179Medulloblastoma 172Carcinoma, Non-Small-Cell Lung 149Recurrence 147Neoplasm Metastasis 138Lung Neoplasms 138Ependymoma 127Melanoma 118Sarcoma 116Neurofibromatosis 1 110Meningeal Carcinomatosis 107Lymphoma 94Neuroma, Acoustic 82Diffuse Intrinsic Pontine Glioma 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Head and Neck Neoplasms 79Ovarian Neoplasms 73Lymphoma, Follicular 73Pheochromocytoma 71Paraganglioma 68

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-positive Metastatic Breast Cancer × CNS × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡